[Combined cytostatic treatment of malignant brain tumors (author's transl)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy*; D001812:Blood-Brain Barrier / Q000187:drug effects; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009002:Monomethylhydrazine / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D014747:Vinblastine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014747:Vinblastine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D005472:Fluorouracil; D009002:Monomethylhydrazine; D008727:Methotrexate
Kombinierte zytostatische Therapie maligner Hirntumoren